A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers

By sjmartinez • October 2, 2026

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark LN, Golmakani M, Jackson-Fisher A, Tang SY, Guo CC, Keliher EJ, Maresca K, Segal NH. A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers. Cancer Res Commun. 2026 Oct 1;6(10):2299-2310. doi: 10.1158/2767-9764.CRC-26-0101. PMID: 42696650; PMCID: PMC13629743.

Tags: Hematology/Oncology, Publications

Psychosocial burden in cancer survivors

Ganz PA. Psychosocial burden in cancer survivors. Nat Rev Cancer. 2026 Oct 1. doi: 10.1038/s41568-026-00986-0. Epub ahead of print. PMID: 42823480.

Delta-9-tetrahydrocannabinol alleviates inflammation by modulating immune responses in LPS-induced murine inflammation model

Tomer S, Harding J, Wang L, Kedia N, Cook E, Le V, Platt C, Le J, Tien N, Patalay K, Langfelder P, Yang XW, Zhang[...]

Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors of Head and Neck Cancer

Lin ME, Stenzel J, Delavary D, St John MA, Wong DJ, Ganz PA, Brauer ER. Self-Reported Cancer-Related Cognitive Impairment and Psychosocial Symptom Burden in Survivors[...]